European Urology Oncology
Papers
331
Papers 447
1 page of 45 pages (447 results)
Newest
#1Umberto Capitanio (UniSR: Vita-Salute San Raffaele University)H-Index: 63
#2Riccardo AutorinoH-Index: 68
Last. Francesco Montorsi (UniSR: Vita-Salute San Raffaele University)H-Index: 139
view all 15 authors...
Source
#1Roberto Contieri (Humanitas University)H-Index: 3
#2Marco Paciotti (Humanitas University)H-Index: 2
Last. Rodolfo HurleH-Index: 22
view all 12 authors...
Active surveillance (AS) has been proposed as an alternative to transurethral resection (TUR) in selected patients with recurrent low-risk non-muscle-invasive bladder cancer (NMIBC). Here we report long-term results for patients on AS and investigate features associated with AS failure. Cases with recurrence after diagnosis of low-grade (LG) pTa/pT1a NMIBC were enrolled in the Bladder Italian Active Surveillance (BIAS) project. Over 251 AS events, we observed 130 failures (51.8%). In these patie...
Source
#1Gaëtan Devos (Katholieke Universiteit Leuven)H-Index: 10
#2Andries Clinckaert (Katholieke Universiteit Leuven)
Last. Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
view all 4 authors...
Source
#1Michael A. Gorin (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 34
#2Hiten D. Patel (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 23
Last. Mohamad E. Allaf (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 57
view all 15 authors...
Neoadjuvant immune checkpoint blockade represents a novel approach for potentially decreasing the risk of recurrence in patients with nonmetastatic renal cell carcinoma (RCC). In this early phase clincal tiral, we evaluated the safety and tolerability of neoadjuvant treatment with the programmed cell death protein 1 (PD-1) inhibitor nivolumab in patients with nonmetastatic high-risk RCC. Nonprimary endpoints included objective radiographic tumor response rate, immune-related pathologic response ...
1 CitationsSource
#1Michael J. Morris (Cornell University)H-Index: 67
#2Jose Mauricio Mota (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 16
Last. Howard I. Scher (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 145
view all 14 authors...
Abstract Background No standard of care exists for patients with high-risk biochemical recurrence (BCR) after prostatectomy. Objective To evaluate whether addition of docetaxel to androgen deprivation therapy (ADT) improved progression-free survival (PFS) in high-risk BCR patients. Design, setting, and participants TAX3503 was a multicenter phase 3 trial that randomized patients with high-risk BCR to ADT for 18 mo ± docetaxel (75 mg/m2 q3w for ten cycles). Eligibility included prostate-specific ...
Source
#1Nicolas MottetH-Index: 39
#2Olivier RouvièreH-Index: 56
Last. Theodorus H. van der Kwast (EUR: Erasmus University Rotterdam)H-Index: 41
view all 3 authors...
1 CitationsSource
#1Shauna R. Campbell (Cleveland Clinic)H-Index: 5
#2M.C. Tom (Baptist Hospital of Miami)H-Index: 1
Last. Rahul D. Tendulkar (Cleveland Clinic)H-Index: 20
view all 13 authors...
BACKGROUND Salvage radiotherapy (SRT) is an established treatment for men with biochemical recurrence following radical prostatectomy (RP). There are several risk factors associated with adverse outcomes; however, the value of postoperative prostate-specific antigen (PSA) kinetics is less clear in the ultrasensitive PSA era. OBJECTIVE To characterize the impact of PSA kinetics on outcomes following SRT and generate nomograms to aid in identifying patients with an increased risk of adverse clinic...
Source
#1Anwar R. Padhani (NU: Northwood University)H-Index: 91
#2Ivo G. Schoots (EUR: Erasmus University Rotterdam)H-Index: 30
Last. Jelle O. Barentsz (Radboud University Nijmegen)H-Index: 92
view all 3 authors...
Source
#1Alessandro RizzoH-Index: 14
#2Veronica MollicaH-Index: 12
Last. Francesco MassariH-Index: 39
view all 3 authors...
Source
#1Elizabeth GreenH-Index: 3
Last. Ashish M. Kamat (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 8 authors...
Abstract Context Bladder and kidney cancers require invasive procedures for definitive diagnosis, and bladder cancer requires repeated procedures to monitor for disease recurrence. Given the recent work to identify molecular alterations in liquid biopsies to diagnose and monitor these diseases, a synthesis of the growing body of evidence is merited. Objective To review current data on cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) and to synthesize their roles in the diagnosis, monitori...
Source
12345678910
Top fields of study
Cancer
Oncology
Prostatectomy
Prostate cancer
Bladder cancer
Medicine